"10.1371_journal.pntd.0002942","plos neglected tropical diseases","2014-06-19T00:00:00Z","Sarah Abdalla Ahmed; Wendy Kloezen; Frederick Duncanson; Ed E Zijlstra; G Sybren de Hoog; Ahmed H Fahal; Wendy W J van de Sande","Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan; Centraalbureau voor Schimmelcultures CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands; Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, The Netherlands; Erasmus MC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands; Eisai Inc., Woodcliff Lake, New Jersey, United States of America; Rotterdam Centre for Tropical Medicine, Rotterdam, The Netherlands; Peking University Health Science Center, Research Center for Medical Mycology, Beijing, China; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China; Shanghai Institute of Medical Mycology, Changzheng Hospital, Second Military Medical University, Shanghai, China; Basic Pathology Department, Federal University of Paraná State, Curitiba, Paraná, Brazil; King Abdulassiz University, Jeddah, Saudi Arabia; Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan","Conceived and designed the experiments: WWJvdS WK EEZ. Performed the experiments: SAA WWJvdS WK. Analyzed the data: SAA WWJvdS. Contributed reagents/materials/analysis tools: WWJvdS AHF FD. Wrote the paper: SAA WWJvdS WK AHF EEZ GSdH FD.","FD is a salaried full time employee of Eisai, Inc. receiving the standard benefits package of the company but having no stock in it. NIAID is studying the compound E5564 for biothreat indications and has no bearing on E1224 or any study conducted in relationship to or with E1224. No travel grants were given, except for business related trips relevant to the companys routine way of conducting business or for presentation to company data at a scientific meeting. He has a collaborative agreement with the Drugs for Neglected Diseases Initiative to examine E1224 for the treatment of chronic indeterminate Chagas disease which has no bearing on this article. His employment with Eisai does not alter, in any way, his adherence to all of the PLOS NTDs policies on sharing data and materials. He does not consider his employment at Eisai Inc. or any facet of his participation in the research or development of the article to interfere in any way with the full and objective presentation, peer review, editorial decision making, or publication of research or non-research articles submitted to PLoS NTD or any related journals. The other authors have declared that no competing interests exist.","2014","06","Sarah Abdalla Ahmed","SAA",7,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
